Table 1 Licensed biologics for severe asthma
DRUG NAME | TARGET | MODE OF ADMINISTRATION | CRITERIA OF PRESCRIPTION | AGE INDICATION | DOSING INTERVAL | DOSAGE |
|---|---|---|---|---|---|---|
Omalizumab | IgE | Subcutaneous injection | high blood IgE; sensititazion to perennial allergen | ≥6 years | 14 days or 28 days | 75 mg to 600 mg (based on kg and tot IgE) |
Mepolizumab | IL-5 | Subcutaneous injection | high blood eosinophils | ≥6 years | 28 days | 100 mg |
Reslizumab | IL-5 | Intravenous injection | high blood eosinophils | ≥ 18 years | 28 days | 3 mg/kg |
Benralizumab | IL-5 receptor a | Subcutaneous injection | high blood eosinophils | ≥ 18 years | 28 days (56 days after 3 months) | 30 mg |
Dupilumab | IL-4 receptor alpha | Subcutaneous injection | high blood eosinophils and/or raised FeNO | ≥12 years | 14 days | 200 mg to 300 mg (based on comorbidities) |